Skip to main content
Erschienen in: Annals of Hematology 12/2019

05.11.2019 | Original Article

Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis

verfasst von: Philipp Riffel, Mohamad Jawhar, Kristina Gawlik, Juliana Schwaab, Henrik J. Michaely, Georgia Metzgeroth, Wolf-Karsten Hofmann, Stefan O. Schoenberg, Andreas Reiter

Erschienen in: Annals of Hematology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Systemic mastocytosis (SM) is broadly subcategorized according to mast cell (MC) burden and organ involvement into indolent (ISM), smoldering (SSM), and advanced SM (AdvSM). However, the pattern and extent of bone involvement remains controversial. In this institutional review board (IRB)-approved study, 115 patients with different forms of SM (ISM (n = 37, 32%), SSM (n = 9, 8%), and AdvSM (n = 69, 60%)) underwent a whole-body magnetic resonance imaging including sagittal and coronal T1 and turbo inversion recovery magnitude (TIRM) sequences of the spine. The evaluation included the pattern and extent of pathologic bone marrow (BM) signals in the spine and extremities, osteolytic lesions, and vertebral fractures. A pathologic BM pattern was observed in 4/37 (11%), 8/9 (89%), and 66/69 (96%); affection of the appendicular skeleton in 3/37 (8%), 8/9 (89%), and 67/69 (97%); and vertebral fractures in 7/37 (19%), 0/9, and 13/69 (19%) patients with ISM, SSM, and AdvSM, respectively. In AdvSM, pathologic BM pattern included activated (62%), diffuse sclerotic (25%), and small-spotted BM (9%), respectively. Only activated/sclerotic BM was associated with significantly higher MC burden, organ damage, and inferior median survival (2.9 years, p = 0.04). Vertebral fractures resembled classical multi-segmental osteoporotic fractures in ISM but not in AdvSM in which they were only found in activated/sclerotic BM. Only one patient with AdvSM had a focal osteolytic lesion in the femur. Activated/sclerotic BM changes of the spine and affection of the appendicular skeleton are indicative for SSM or AdvSM. Osteolytic lesions, which are very rare, and osteoporotic fractures are ineligible for the diagnosis of AdvSM.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD (2003) Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122:695–717CrossRef Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD (2003) Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122:695–717CrossRef
3.
Zurück zum Zitat Horny HP, Parwaresch MR, Lennert K (1985) Bone marrow findings in systemic mastocytosis. Hum Pathol 16:808–814CrossRef Horny HP, Parwaresch MR, Lennert K (1985) Bone marrow findings in systemic mastocytosis. Hum Pathol 16:808–814CrossRef
4.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefPubMed Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefPubMed
5.
Zurück zum Zitat Valent P, Akin C, Metcalfe DD (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 129:1420–1427CrossRefPubMed Valent P, Akin C, Metcalfe DD (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 129:1420–1427CrossRefPubMed
7.
Zurück zum Zitat Pardanani A (2016) Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol 91:1146–1159CrossRef Pardanani A (2016) Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol 91:1146–1159CrossRef
8.
Zurück zum Zitat Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, Haferlach T, Schmitt K, Fabarius A, Valent P, Hofmann WK, Cross NCP, Metzgeroth G, Reiter A (2017) The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica 102:1035–1043CrossRefPubMed Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, Haferlach T, Schmitt K, Fabarius A, Valent P, Hofmann WK, Cross NCP, Metzgeroth G, Reiter A (2017) The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica 102:1035–1043CrossRefPubMed
9.
Zurück zum Zitat Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, Metzgeroth G, Fabarius A, Valent P, Hofmann WK, Cross NCP, Meggendorfer M, Reiter A (2017) Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood 130:137–145CrossRef Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, Metzgeroth G, Fabarius A, Valent P, Hofmann WK, Cross NCP, Meggendorfer M, Reiter A (2017) Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood 130:137–145CrossRef
10.
Zurück zum Zitat Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A (2016) Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia 30:136–143CrossRef Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A (2016) Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia 30:136–143CrossRef
11.
Zurück zum Zitat Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, Horny HP, Sotlar K, Schoenberg SO, Cross NC, Fabarius A, Hofmann WK, Valent P, Metzgeroth G, Reiter A (2016) Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia 30:2342–2350CrossRef Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, Horny HP, Sotlar K, Schoenberg SO, Cross NC, Fabarius A, Hofmann WK, Valent P, Metzgeroth G, Reiter A (2016) Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia 30:2342–2350CrossRef
12.
Zurück zum Zitat Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A (2013) Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 122:2460–2466CrossRef Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A (2013) Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 122:2460–2466CrossRef
13.
Zurück zum Zitat Metzgeroth G, Dinter D, Erben P, La Rosee P, Hehlmann R, Hastka J (2007) Systemic mastocytosis simulating osseous metastatic disease. Br J Haematol 136:1CrossRef Metzgeroth G, Dinter D, Erben P, La Rosee P, Hehlmann R, Hastka J (2007) Systemic mastocytosis simulating osseous metastatic disease. Br J Haematol 136:1CrossRef
14.
Zurück zum Zitat Deb A, Tefferi A (2003) Images in clinical medicine. Systemic mastocytosis N Engl J Med 349:e7CrossRef Deb A, Tefferi A (2003) Images in clinical medicine. Systemic mastocytosis N Engl J Med 349:e7CrossRef
15.
Zurück zum Zitat Myers B, Grimley C, Jones SG, Clark D, Kerslake R (2003) Skin, bone marrow and magnetic resonance imaging appearances in systemic mastocytosis. Br J Haematol 122:876CrossRef Myers B, Grimley C, Jones SG, Clark D, Kerslake R (2003) Skin, bone marrow and magnetic resonance imaging appearances in systemic mastocytosis. Br J Haematol 122:876CrossRef
16.
Zurück zum Zitat Epelboym Y, Keraliya AR, Tirumani SH, Hornick JL, Ramaiya NH, Shinagare AB (2017) Differences in the imaging features and distribution of non-indolent and indolent mastocytosis: a single institution experience of 29 patients. Clin Imaging 44:111–116CrossRef Epelboym Y, Keraliya AR, Tirumani SH, Hornick JL, Ramaiya NH, Shinagare AB (2017) Differences in the imaging features and distribution of non-indolent and indolent mastocytosis: a single institution experience of 29 patients. Clin Imaging 44:111–116CrossRef
17.
Zurück zum Zitat Huang TY, Yam LT, Li CY (1987) Radiological features of systemic mast-cell disease. Br J Radiol 60:765–770CrossRef Huang TY, Yam LT, Li CY (1987) Radiological features of systemic mast-cell disease. Br J Radiol 60:765–770CrossRef
18.
Zurück zum Zitat Avila NA, Ling A, Metcalfe DD, Worobec AS (1998) Mastocytosis: magnetic resonance imaging patterns of marrow disease. Skelet Radiol 27:119–126CrossRef Avila NA, Ling A, Metcalfe DD, Worobec AS (1998) Mastocytosis: magnetic resonance imaging patterns of marrow disease. Skelet Radiol 27:119–126CrossRef
19.
Zurück zum Zitat Roca M, Mota J, Giraldo P, Garcia Erce JA (1999) Systemic mastocytosis: MRI of bone marrow involvement. Eur Radiol 9:1094–1097CrossRef Roca M, Mota J, Giraldo P, Garcia Erce JA (1999) Systemic mastocytosis: MRI of bone marrow involvement. Eur Radiol 9:1094–1097CrossRef
20.
Zurück zum Zitat Siegel S, Sadler MA, Yook C, Chang V, Miller J (1999) Systemic mastocytosis with involvement of the pelvis: a radiographic and clinicopathologic study--a case report. Clin Imaging 23:245–248CrossRef Siegel S, Sadler MA, Yook C, Chang V, Miller J (1999) Systemic mastocytosis with involvement of the pelvis: a radiographic and clinicopathologic study--a case report. Clin Imaging 23:245–248CrossRef
21.
Zurück zum Zitat Di Leo C, Lodi A, Pozzato C et al (2003) Systemic mastocytosis: bone marrow involvement assessed by Tc-99m MDP scintigraphy and magnetic resonance imaging. Haematologica 88:Ecr26 Di Leo C, Lodi A, Pozzato C et al (2003) Systemic mastocytosis: bone marrow involvement assessed by Tc-99m MDP scintigraphy and magnetic resonance imaging. Haematologica 88:Ecr26
22.
Zurück zum Zitat Sperr WR, Valent P (2012) Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol 5:261–274CrossRef Sperr WR, Valent P (2012) Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol 5:261–274CrossRef
23.
Zurück zum Zitat Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67:345–368CrossRef Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67:345–368CrossRef
24.
Zurück zum Zitat Armingaud P, Zerkak D, Lespessailles E et al (2002) Bone evaluation in ten adults with cutaneous mastocytosis. Ann Dermatol Venereol 129:170–172 Armingaud P, Zerkak D, Lespessailles E et al (2002) Bone evaluation in ten adults with cutaneous mastocytosis. Ann Dermatol Venereol 129:170–172
25.
Zurück zum Zitat Grieser T, Minne HW (1997) Systemic mastocytosis and skeletal lesions. Lancet 350:1103–1104CrossRef Grieser T, Minne HW (1997) Systemic mastocytosis and skeletal lesions. Lancet 350:1103–1104CrossRef
26.
Zurück zum Zitat Brumsen C, Hamdy NA, Papapoulos SE (2002) Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17:567–569CrossRef Brumsen C, Hamdy NA, Papapoulos SE (2002) Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17:567–569CrossRef
27.
Zurück zum Zitat Lim AY, Ostor AJ, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965–966CrossRefPubMed Lim AY, Ostor AJ, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965–966CrossRefPubMed
28.
Zurück zum Zitat Jawhar M, Schwaab J, Horny HP, Sotlar K, Naumann N, Fabarius A, Valent P, Cross NC, Hofmann WK, Metzgeroth G, Reiter A (2016) Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Investig 46:392–397CrossRef Jawhar M, Schwaab J, Horny HP, Sotlar K, Naumann N, Fabarius A, Valent P, Cross NC, Hofmann WK, Metzgeroth G, Reiter A (2016) Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Investig 46:392–397CrossRef
29.
Zurück zum Zitat Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, Dubreuil P, Arock M, Roux C, Launay JM, Fraitag S, Canioni D, Billemont B, Suarez F, Lanternier F, Lortholary O, Hermine O, Francès C (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838–1841CrossRef Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, Dubreuil P, Arock M, Roux C, Launay JM, Fraitag S, Canioni D, Billemont B, Suarez F, Lanternier F, Lortholary O, Hermine O, Francès C (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838–1841CrossRef
30.
Zurück zum Zitat Kluin-Nelemans HC, Jansen JH, Breukelman H et al (1992) Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326:619–623CrossRef Kluin-Nelemans HC, Jansen JH, Breukelman H et al (1992) Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326:619–623CrossRef
31.
Zurück zum Zitat Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, Vecchiato D, Bonifacio M, Viapiana O, Gatti D, Senna G, Riccio A, Passalacqua G, Pizzolo G, Adami S (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49:880–885CrossRef Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, Vecchiato D, Bonifacio M, Viapiana O, Gatti D, Senna G, Riccio A, Passalacqua G, Pizzolo G, Adami S (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49:880–885CrossRef
32.
Zurück zum Zitat Manara M, Varenna M, Cantoni S, Parafioriti A, Gallazzi MB, Sinigaglia L (2010) Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases. Clin Exp Rheumatol 28:97–100 Manara M, Varenna M, Cantoni S, Parafioriti A, Gallazzi MB, Sinigaglia L (2010) Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases. Clin Exp Rheumatol 28:97–100
33.
Zurück zum Zitat Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344–350CrossRef Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344–350CrossRef
34.
Zurück zum Zitat Brockow K, Akin C, Huber M, Metcalfe DD (2005) IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 115:216–223CrossRef Brockow K, Akin C, Huber M, Metcalfe DD (2005) IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 115:216–223CrossRef
35.
Zurück zum Zitat Kanzaki S, Takahashi T, Kanno T, Ariyoshi W, Shinmyouzu K, Tujisawa T, Nishihara T (2008) Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. J Cell Physiol 216:844–850CrossRef Kanzaki S, Takahashi T, Kanno T, Ariyoshi W, Shinmyouzu K, Tujisawa T, Nishihara T (2008) Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. J Cell Physiol 216:844–850CrossRef
36.
Zurück zum Zitat Johansson C, Roupe G, Lindstedt G, Mellstrom D (1996) Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 25:1–7CrossRef Johansson C, Roupe G, Lindstedt G, Mellstrom D (1996) Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 25:1–7CrossRef
Metadaten
Titel
Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis
verfasst von
Philipp Riffel
Mohamad Jawhar
Kristina Gawlik
Juliana Schwaab
Henrik J. Michaely
Georgia Metzgeroth
Wolf-Karsten Hofmann
Stefan O. Schoenberg
Andreas Reiter
Publikationsdatum
05.11.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 12/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03826-4

Weitere Artikel der Ausgabe 12/2019

Annals of Hematology 12/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.